Efficacy of apremilast in hyperkeratotic hand and foot dermatitis: results from a randomized observer-blinded comparative study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Blackwell Science Country of Publication: England NLM ID: 0243704 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-4632 (Electronic) Linking ISSN: 00119059 NLM ISO Abbreviation: Int J Dermatol Subsets: MEDLINE
    • Publication Information:
      Publication: Oxford : Blackwell Science
      Original Publication: Philadelphia, Lippincott.
    • Subject Terms:
      Thalidomide*/analogs & derivatives ; Thalidomide*/administration & dosage ; Thalidomide*/therapeutic use ; Thalidomide*/adverse effects ; Severity of Illness Index* ; Hand Dermatoses*/drug therapy ; Hand Dermatoses*/diagnosis ; Foot Dermatoses*/drug therapy ; Foot Dermatoses*/diagnosis ; Quality of Life* ; Mometasone Furoate*/administration & dosage; Humans ; Male ; Female ; Adult ; Middle Aged ; Treatment Outcome ; Drug Therapy, Combination ; Single-Blind Method ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Pruritus/drug therapy ; Pruritus/etiology ; Pruritus/diagnosis ; Administration, Oral ; Keratosis/drug therapy ; Keratosis/diagnosis ; Administration, Cutaneous ; Skin Cream/administration & dosage ; Young Adult
    • Abstract:
      Background: Hyperkeratotic hand and foot dermatitis significantly affects quality of life. Some patients respond suboptimally to topical corticosteroids and have multiple recurrences.
      Objective: Our aim was to compare the efficacy and safety profile of apremilast and topical corticosteroid versus corticosteroid alone in hyperkeratotic hand and foot dermatitis.
      Methods: This randomized controlled study involved 77 patients treated for 3 months. Group A (39 patients) received mometasone furoate 0.1% cream with oral apremilast 30 mg twice daily, and Group B (38 patients) received mometasone alone. They were assessed monthly using the Hand Eczema Clinical Severity Index (HECSI) and Visual Analogue Scale (VAS) scores for pruritus. Investigator Global Assessment (IGA) and Quality of Life in Hand Eczema Questionnaire (QOLHEQ) were conducted at the end of 3 months.
      Results: The HECSI, VAS score, and QOLHEQ showed a significant decrease in both groups from baseline to the third month. Intergroup comparisons of HECSI failed to reach the significance level. When compared, patients receiving apremilast had significantly better improvement in the third month according to the Patient Global Assessment (PGA) and Investigator Global Assessment (IGA). They also had a smaller number of flares.
      Conclusion: Adding apremilast to topical corticosteroid leads to better patient and physician-perceived improvement and reduces the number of flares in hyperkeratotic hand eczema.
      (© 2024 the International Society of Dermatology.)
    • References:
      Diepgen TL, Agner T, Aberer W, Berth‐Jones J, Cambazard F, Elsner P, et al. Management of chronic hand eczema. Contact Derm. 2007;57:203–210.
      Afra TP, Razmi TM, Dogra S. Apremilast in psoriasis and beyond: big hopes on a small molecule. Indian Dermatol Online J. 2019;10:1–2.
      Agarwal US, Besarwal RK. Topical clobetasol propionate 0.05% cream alone and in combination with azathioprine in patients with chronic hand eczema: an observer blinded randomized comparative trial. Indian J Dermatol Venereol Leprol. 2013;79:101–103.
      Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, et al. Apremilast, an oral phosphodiesterase‐4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR‐005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75:99–105.
      Schnopp C, Remling R, Möhrenschlager M, Weigl L, Ring J, Abeck D. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer‐blinded trial. J Am Acad Dermatol. 2002;46:73–77.
      Hanifin JM, Stevens V, Sheth P, Breneman D. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol. 2004;150:545–553.
      Veien NK, Olholm Larsen P, Thestrup‐Pedersen K, Schou G. Long‐term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol. 1999;140:882–886.
      Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter‐ and intraobserver reliability. Br J Dermatol. 2005;152:302–307.
      Granlund H, Erkko P, Eriksson E, Reitamo S. Comparison of cyclosporine and topical betamethasone‐17,21‐dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol. 1996;76:371–376.
      Ruzicka T, Larsen FG, Galewicz D, Attila H, Coenraads T, et al. Oral alitretinoin (9‐cis‐retinoic acid) therapy for chronic hand dermatitis in patient's refractory to standard therapy: results of a randomized, double‐blind, placebo‐controlled, multicenter trial. Arch Dermatol. 2004;140:1453–1459.
      Song M, Lee HJ, Lee WK, Kim HS, Ko HC, Kim MB, et al. Acitretin as a therapeutic option for chronic hand eczema. Annal Dermatol. 2017;29(3):385–387.
      Abrouk M, Farahnik B, Zhu TH, Mio N, Singh R, Lee K, et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol. 2017;77:177–180.
      Ofenloch RF, Weisshaar E, Dumke AK, Molin S, Diepgen TL, Apfelbacher C. The Quality of Life in Hand Eczema Questionnaire (QOLHEQ): validation of the German version of a new disease‐specific measure of quality of life for patients with hand eczema. Br J Dermatol. 2014;171:304–312.
      Paul C, Cather J, Gooderham M, Poulin Y, Meowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–1399.
    • Contributed Indexing:
      Keywords: apremilast; hand dermatitis; hyperkeratotic; mometasone; relapse
    • Accession Number:
      UP7QBP99PN (apremilast)
      4Z8R6ORS6L (Thalidomide)
      04201GDN4R (Mometasone Furoate)
      0 (Anti-Inflammatory Agents, Non-Steroidal)
    • Publication Date:
      Date Created: 20240517 Date Completed: 20241019 Latest Revision: 20241114
    • Publication Date:
      20241115
    • Accession Number:
      10.1111/ijd.17185
    • Accession Number:
      38757673